Pheburane® is a taste-masked oral formulation of sodium phenylbutyrate, approved by the Food and Drug Administration as adjunctive therapy to standard of care, which includes dietary management, for ...
PRINCETON, NJ, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Medunik USA is pleased to announce the availability of Pheburane® oral pellets, a unique taste-masked formulation of sodium phenylbutyrate (NaPB).
PRINCETON, N.J., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Medunik USA (member of Duchesnay Pharmaceutical Group, an international company selected in the Government of Canada's first Global Hypergrowth ...
(MENAFN- GlobeNewsWire - Nasdaq) PRINCETON, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Medunik USA (member of duchesnay Pharmaceutical group ) is pleased to announce that an increasing number of ...
to their Medicaid Preferred Drug lists, namely Florida, Louisiana, and Maine, with Florida being one of the top states in terms of Medicaid spending on Urea Cycle Disorder (UCD) treatments. Thus, ...
PRINCETON, NJ, Jan. 23, 2024 /PRNewswire/ - Medunik USA, member of Duchesnay Pharmaceutical Group (DPG) one of the few anchor companies selected by the Government of Canada for its Global Hypergrowth ...
PRINCETON, N.J., Nov. 4, 2025 /PRNewswire/ - Medunik USA, a specialty pharmaceutical company dedicated to providing rare disease patients with access to orphan drugs, and part of Duchesnay ...
PRINCETON, NJ, May 17, 2023 (GLOBE NEWSWIRE) -- Medunik USA (member of Duchesnay Pharmaceutical Group) is pleased to announce that Pheburane® is now covered with preferred status at key pharmacy ...
Pheburane® is the safe, effective, and palatable adjunctive therapy to the standard of care, which includes dietary management, for the treatment of certain urea cycle disorders (UCDs). Pheburane® is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results